Abzena Ltd, a contract research and development company for biologics and bioconjugates, has appointed Geoffrey M. Glass as chief executive officer to lead Abzena in its next growth phase. Mr Glass has been chairman of Abzena’s board since 2022 and has 30 years of experience in the life sciences industry, including roles helping to build the CDMO sector over the last 15 years. Previous executive roles include at EY Consulting, Valeant Pharmaceuticals (now Bausch Health) and Patheon (now Thermo Fisher Scientific).
Copyright 2025 Evernow Publishing Ltd